Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.33 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.32 |
| ▸ | S1PR4 | O95977 | 3/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 3/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22951263 | 0.93 | S1PR4 (0.32) | FDPSSMPD1GGPS1S1PR4S1PR1 | |
| SCHEMBL23634141 | 0.93 | S1PR4 (0.32) | FDPSSMPD1GGPS1S1PR4S1PR1 | |
| SCHEMBL18557087 | 0.74 | TLR8 (0.36) | CNR2 | |
| SCHEMBL24414188 | 0.74 | TLR8 (0.36) | CNR2 | |
| SCHEMBL18612488 | 0.74 | TLR8 (0.36) | CNR2 | |
| SCHEMBL18760500 | 0.74 | TLR8 (0.36) | CNR2 | |
| SCHEMBL18852694 | 0.73 | TLR8 (0.36) | CNR2 | |
| SCHEMBL18793072 | 0.73 | TLR8 (0.36) | CNR2 | |
| SCHEMBL23502540 | 0.72 | CNR2 (0.34) | FDPSGGPS1CNR2 | |
| SCHEMBL23502537 | 0.72 | CNR2 (0.34) | FDPSGGPS1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | FDPS 289/4885SMPD1 3339/4885GGPS1 1032/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | FDPS 289/4885SMPD1 3339/4885GGPS1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.